… Structure-based computational approach for optimizing oligonucleotides for A-to-I editing Applicability … J Boudet et al. A robust computational approach is developed to screen for compatible interactions between …
… sepofarsen captain. The work of her department, aimed at developing a novel drug for Leber congenital amaurosis 10 … in Venezuela and now heading ProQR’s LCA research and development team in Leiden (The Netherlands), has multiple reasons for being optimistic. Obviously, as a biotech scientist looking for a …
… because it requires you to really attach yourself to one topic for four years, and that’s not my personality. I started looking at the Science Park here in Leiden for options. At the time ProQR was looking for five technicians, … that what works. The past year we have been working on optimizing protocols to grow cells from a patient’s skin into …
… long before that Gerard Platenburg was involved in the development of RNA therapies. Even so, after decades of … RNA therapies.” But what about gene therapy, isn’t that an option? “There are several reasons to choose RNA therapy over … Can we learn more about our molecules, and does it help to optimize our protocols? Those are just some of the questions …
… with Lilly and Company . The partnership focuses on developing potential medicines using our Axiomer ® RNA … is to progress new medicine technology towards clinical development and, ultimately, to patients via … into diseases of which there are little to no treatment options. In our vision partnerships are true catalyst for the …
… collaboration with Lilly. The partnership focuses on developing potential medicines using our Axiomer RNA editing … beginning, ProQR has been focused on RNA technologies to develop medicines for people and families with high unmet … additional targets, along with an option for Lilly to opt in for more. Lilly is a leader in RNA therapeutics, and …
Bart Klein was at the forefront of ProQR's Axiomer® RNA editing technology development. This platform technology makes it possible to use the cells own machinery to reverse mutations that cause a genetic disease. Read the interview.
This presentation highlights the therapeutic possibilities of Axiomer platform that are not limited to disease causing mutations and can potentially address high unmet medical needs by editing wild-type RNA to engineer proteins or modify their function as well as creating de novo mutations.
… presentations by ProQR Management on the company's proprietary Axiomer® RNA editing technology platform, … editing in humans. In addition, his group has led in the development of structure-guided methods for optimizing chemically modified oligonucleotides for …
